Literature DB >> 22271914

Chronic myeloid leukemia: the race is yet to be won.

Jorge Cortes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22271914      PMCID： PMC3348186          DOI： 10.1503/cmaj.111710

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Hagop Kantarjian; Neil P Shah; Andreas Hochhaus; Jorge Cortes; Sandip Shah; Manuel Ayala; Beatriz Moiraghi; Zhixiang Shen; Jiri Mayer; Ricardo Pasquini; Hirohisa Nakamae; Françoise Huguet; Concepción Boqué; Charles Chuah; Eric Bleickardt; M Brigid Bradley-Garelik; Chao Zhu; Ted Szatrowski; David Shapiro; Michele Baccarani
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

Authors:  David Marin; Alexandra Bazeos; Francois-Xavier Mahon; Lina Eliasson; Dragana Milojkovic; Marco Bua; Jane F Apperley; Richard Szydlo; Ritti Desai; Kasia Kozlowski; Christos Paliompeis; Victoria Latham; Letizia Foroni; Mathieu Molimard; Alistair Reid; Katy Rezvani; Hugues de Lavallade; Cristina Guallar; John Goldman; Jamshid S Khorashad
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

3.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

4.  Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia.

Authors:  Aref Al-Kali; Hagop Kantarjian; Jianqin Shan; Roland Bassett; Alfonso Quintás-Cardama; Gautam Borthakur; Elias Jabbour; Srdan Verstovsek; Susan O'Brien; Jorge Cortes
Journal:  Cancer       Date:  2010-09-15       Impact factor: 6.860

5.  Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.

Authors:  Neil P Shah; Dong-Wook Kim; Hagop Kantarjian; Philippe Rousselot; Pedro Enrique Dorlhiac Llacer; Alicia Enrico; Jorge Vela-Ojeda; Richard T Silver; Hanna Jean Khoury; Martin C Müller; Alexandre Lambert; Yousif Matloub; Andreas Hochhaus
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

6.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

7.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.

Authors:  Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

8.  Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Authors:  Hagop Kantarjian; Susan O'Brien; Elias Jabbour; Jenny Shan; Farhad Ravandi; Tapan Kadia; Stefan Faderl; Guillermo Garcia-Manero; Gautam Borthakur; Jorge Cortes
Journal:  J Clin Oncol       Date:  2011-07-11       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.